Iasoflu

Sodium Fluoride, the active ingredient in Iasoflu, is a radiopharmaceutical presented as an injectable solution for intravenous use. It enables PET imaging of bone metabolism and is employed to detect bone metastases and evaluate skeletal disorders in patients requiring detailed bone assessment.

GNH USA supplies Iasoflu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and clinics worldwide.

Iasoflu is a bone‑seeking radiotracer used in PET imaging to assess skeletal pathology.

- Bone metastases detection: enables visualization of metastatic lesions in bone using PET imaging. - Skeletal disorder evaluation: assists in diagnosing conditions such as Paget disease or osteomyelitis by highlighting areas of altered bone turnover. - General bone metabolism imaging: provides quantitative data on bone remodeling for research and clinical monitoring.

Adverse reactions may occur following intravenous administration of Iasoflu.

Common Side Effects: - Injection site pain or erythema. - Mild nausea or transient flushing. - Headache or dizziness. - Warmth sensation during uptake period.

Serious or Rare Side Effects: - Allergic reaction or anaphylaxis. - Severe hypotension or cardiovascular collapse. - Radiation‑induced skin injury at the injection site. - Acute renal impairment in susceptible patients.

Iasoflu should be used with attention to patient safety and proper handling.

- Renal function assessment: evaluate renal clearance before administration. - Pregnancy considerations: avoid use unless the diagnostic benefit outweighs potential fetal risk. - Breastfeeding: discontinue breastfeeding or consider alternative imaging if possible. - Concomitant radiation therapy: schedule imaging to avoid interference with therapeutic doses. - Hypersensitivity: do not administer to patients with known allergy to sodium fluoride or similar agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential interactions may affect image quality or patient safety.

Major Interactions (Avoid): - Other PET radiotracers given within 24 h: may cause overlapping signals and inaccurate interpretation. - Recent therapeutic radiation (within 48 h): can alter tracer distribution and compromise diagnostic value.

Moderate Interactions (Monitor Closely): - Calcium supplements or bisphosphonates: may reduce skeletal uptake of the tracer. - Drugs affecting renal clearance (e.g., high‑dose NSAIDs): could modify tracer elimination. - Contrast agents used in CT: coordinate timing to prevent imaging artifacts.